Allogene Therapeutics reported a narrower-than-expected loss for Q4 2024, with an EPS of -$0.28, surpassing the forecast of -$0.32. The company’s stock responded positively, rising 3.66% in ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Hello. Thank you for standing by, and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions] Please be aware that, today's conference call is ...

Allogene Therapeutics reported a narrower-than-expected loss for Q4 2024, with an EPS of -$0.28, surpassing the forecast of -$0.32. The company’s stock responded positively, rising 3.66% in ...

Wednesday - Erste Group has initiated coverage on Spotify (NYSE:SPOT) with a Buy rating, pointing to the company's strong revenue ...